Rhythm Pharmaceuticals to Report First Quarter 2025 Financial Results on Wednesday, May 7, 2025

Core Viewpoint - Rhythm Pharmaceuticals, Inc. will host a live conference call on May 7, 2025, to report its first quarter 2025 financial results and provide a corporate update [1]. Company Overview - Rhythm Pharmaceuticals is a commercial-stage biopharmaceutical company focused on rare neuroendocrine diseases [4]. - The company's lead product, IMCIVREE® (setmelanotide), is an MC4R agonist approved by the FDA for treating obesity and maintaining weight reduction in patients aged 2 years and older with specific genetic conditions [4][5]. - Setmelanotide is also authorized by the European Commission and the UK's MHRA for similar indications in adults and children [4][6]. - Rhythm is advancing a clinical development program for setmelanotide in other rare diseases and is exploring investigational MC4R agonists and small molecules for congenital hyperinsulinism [4]. Product Indications - In the U.S., setmelanotide is indicated for reducing excess body weight in patients with syndromic or monogenic obesity due to Bardet-Biedl syndrome (BBS) or specific genetic deficiencies [5]. - In the EU and UK, it is indicated for obesity treatment and hunger control associated with genetically confirmed BBS or loss-of-function biallelic POMC, PCSK1, or LEPR deficiencies [6]. Safety and Adverse Reactions - Common adverse reactions (≥20% incidence) include skin hyperpigmentation, injection site reactions, nausea, headache, diarrhea, abdominal pain, vomiting, depression, and spontaneous penile erection [15]. - Serious hypersensitivity reactions have been reported, and the drug is contraindicated in patients with prior serious hypersensitivity to setmelanotide [7][12].